Skip to main content

Originally published March 19, 2014 at 7:23 AM | Page modified March 20, 2014 at 6:40 AM

  • Share:
  • Comments ((0))
  • Print

Bothell biotech firm Alder plans $115M IPO

Bothell’s Alder Biopharmaceuticals is filing plans for an initial public offering to raise up to $115 million.

By Seattle Times business staff

No comments have been posted to this article.


Alder Biopharmaceuticals of Bothell has joined an industrywide rush to go public, filing plans Wednesday for an initial public offering to raise up to $115 million.

The clinical-stage biotechnology company has two product candidates, both discovered by Alder, in the early testing stage — one to prevent migraines and one to treat rheumatoid arthritis and psoriatic arthritis.

Alder is partnered with Bristol-Myers Squibb on developing the arthritis product and so far has received $103 million from the drug giant.

The company also says its proprietary technology for creating monoclonal antibodies in yeast cells “offers distinct advantages over traditional mammalian cell culture approaches widely used in the manufacturing of antibodies.”

Launched a decade ago, Alder has accumulated a deficit of $145  million, according to its IPO filing.

Last year it reaped $18.8 million from collaboration and licensing deals and posted a net loss of $20.6 million. It had $23 million in cash on hand at year-end.

Proceeds of the IPO will be used to put the migraine drug through a phase II clinical trial with high-frequency migraine patients, and to pursue other drug research.

The filing does not indicate how many shares Alder aims to sell, or the expected price range.

Alder’s president and CEO is Randall Schatzman, who co-founded the company in 2004. Previously he was senior vice president of discovery research at Celltech R & D, a wholly owned subsidiary of Celltech Group.

Four weeks for 99 cents of unlimited digital access to The Seattle Times. Try it now!

News where, when and how you want it

Email Icon

 Subscribe today!

Subscribe today!

99¢ for four weeks of unlimited digital access.



The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited content access is included with most subscriptions.

Subscriber login ►